SANGUI BIOTECH INTERNATIONAL INC
SANGUI BIOTECH INTERNATIONAL INC (SGBI): 8 pipeline candidates · ~1 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.2 months
D/E -3.10 · 0% dilution
Lead: Approved
8 candidates
N/A
N/A
A transparent, data-derived signal for SANGUI BIOTECH INTERNATIONAL INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$7K
Quarterly Burn
$42K
Runway
1.2 mo
Revenue
$19K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| chitoskin | Approved |
| chronalco i.d.cdt assay | — |
| granulox | Approved |
| hemoglobin-based artificial oxygen carriers | Preclinical |
| hemospray | Approved |
| mib-725 | Phase 1 |
| sangui biotech | — |
| sbt102 | Preclinical |
Frequently asked questions
How many drug candidates are in SANGUI BIOTECH INTERNATIONAL INC's pipeline?
SANGUI BIOTECH INTERNATIONAL INC (SGBI) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is SANGUI BIOTECH INTERNATIONAL INC's lead drug candidate?
SANGUI BIOTECH INTERNATIONAL INC's most advanced tracked candidate is chitoskin (Approved) for chronic wounds.
What is SANGUI BIOTECH INTERNATIONAL INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SANGUI BIOTECH INTERNATIONAL INC has approximately 1.2 months of cash runway.
Get the full picture on SANGUI BIOTECH INTERNATIONAL INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.